Literature DB >> 18839385

The role of CT and ¹⁸F-FDG PET in managing the neck in node-positive head and neck cancer after chemoradiotherapy.

Hidenori Inohara1, Keisuke Enomoto, Yoichiro Tomiyama, Tadashi Yoshii, Yasuhiro Osaki, Ichiro Higuchi, Takehiro Inoue, Jun Hatazawa.   

Abstract

CONCLUSION: Patients showing a complete response on computed tomography (CT) can be spared from neck dissection.
OBJECTIVE: To determine whether CT or fluorine-18-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) is superior in the evaluation of persistent nodal disease after chemoradiotherapy in patients with node-positive head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS: Study entry criteria included node-positive HNSCC treated with definitive chemoradiotherapy, a local complete response, and post-treatment CT and (18)F-FDG PET studies 7 weeks after chemoradiotherapy. Forty-eight patients with 60 node-positive necks were eligible. Nodes larger than 1 cm, or with central necrosis on CT, or any visually hypermetabolic nodes on (18)F-FDG PET were considered positive. Regardless of PET findings, necks with positive CT were subjected to neck dissection, whereas those with negative CT were observed without neck dissection.
RESULTS: Twenty-two necks showed positive CT, 20 and 2 of which underwent neck dissection and fine needle aspiration cytology, respectively, resulting in pathologic evidence of persistent nodal disease in 13 necks. Five of 38 necks with negative CT developed regional recurrence. Diagnostic accuracy was equivalent between CT and (18)F-FDG PET. There was no difference in 3-year cause-specific survival between patients with positive and negative CT (79% and 81%, respectively).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18839385     DOI: 10.1080/00016480802441747

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  7 in total

1.  Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis.

Authors:  Tejpal Gupta; Zubin Master; Sadhana Kannan; Jai Prakash Agarwal; Sarbani Ghsoh-Laskar; Venkatesh Rangarajan; Vedang Murthy; Ashwini Budrukkar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-19       Impact factor: 9.236

Review 2.  PET imaging biomarkers in head and neck cancer.

Authors:  Sarah Differding; François-Xavier Hanin; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

Review 3.  (18)F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications.

Authors:  Gianpiero Manca; Eleonora Vanzi; Domenico Rubello; Francesco Giammarile; Gaia Grassetto; Ka Kit Wong; Alan C Perkins; Patrick M Colletti; Duccio Volterrani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-19       Impact factor: 9.236

4.  Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer.

Authors:  D J Sher; R B Tishler; D Annino; R S Punglia
Journal:  Ann Oncol       Date:  2009-10-15       Impact factor: 32.976

5.  Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck.

Authors:  Lale Kostakoglu; Reza Fardanesh; Marshall Posner; Peter Som; Srikar Rao; Eunice Park; John Doucette; Evan G Stein; Vishal Gupta; Krzysztof Misiukiewicz; Eric Genden
Journal:  Oncologist       Date:  2013-09-13

Review 6.  Advances in the management of squamous cell carcinoma of the head and neck.

Authors:  Jean-Pascal Machiels; Maarten Lambrecht; François-Xavier Hanin; Thierry Duprez; Vincent Gregoire; Sandra Schmitz; Marc Hamoir
Journal:  F1000Prime Rep       Date:  2014-06-02

7.  Clinical significance of the post-radiotherapy 18F-fludeoxyglucose positron emission tomography response in nasopharyngeal carcinoma.

Authors:  Yuri Jeong; In-Hye Jung; Jae Seung Kim; Sei Kyung Chang; Sang-Wook Lee
Journal:  Br J Radiol       Date:  2019-01-03       Impact factor: 3.039

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.